Oct 11 (Reuters) - People who abuse the prescription paindrug Opana ER by injecting it into their bloodstream riskdeveloping a serious blood disorder that could result in kidneyfailure or death, U.S. health regulators warned on Thursday.
Opana is produced by Endo Pharmaceuticals .
The blood disorder, thrombotic thrombocytopenic purpura,resulted in kidney failure requiring dialysis in some cases, andat least one death, the Food and Drug Administration said.
The disorder causes clots to form in small blood vesselsthroughout the body, limiting or blocking blood flow to theorgans.
Platelets, a certain type of blood cell, help the clottingprocess. When this disorder occurs, however, platelets clumptogether in the blood clots, making fewer platelets available inthe blood in other parts of the body to help clotting there.
This can lead to bleeding under the skin and purple-coloredspots called purpura, or to bleeding inside the body.
Thrombotic thrombocytopenic purpura can cause death or leadto other complications with permanent damage, including braindamage and stroke, in addition to kidney failure.
The FDA said problems appear to occur with Opana ER onlywhen it is abused and injected intravenously. Opana ER is meantto be taken orally, and should be taken only when prescribed andas directed.
(Reporting by Debra Sherman in Chicago; Editing by Dale Hudson)
Keywords: OPANA WARNING/